Abbvie, US reach agreement to cut drug prices
Jan 12 (Reuters) - Abbvie reached a three-year agreement with U.S. President Donald Trump's administration to provide low prices in Medicaid through TrumpRx, and pledged $100 billion over the next decade for research and development in the U.S., the company said on Monday.
(Reporting by Ruchika Khanna in Bengaluru; Editing by Chris Reese)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Citi Returns to Prologis (PLD) with Buy Rating and $145 Target
BlockDAG is Drawing Global Trader Focus: 4 Key Indicators It’s the Best Crypto to Buy Now
Bernstein Launches Coverage of Equinix (EQIX), Calls it a Data Center "Juggernaut"
Cipher Digital Shares Drop Amid Uncertainty Over Its Future Direction
Trending news
MoreCrypto prices
More
